LeMaitre Vascular (NASDAQ:LMAT) Updates FY 2025 Earnings Guidance

LeMaitre Vascular (NASDAQ:LMAT) issued an update on its FY 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 2.150-2.320 for the period, compared to the consensus EPS estimate of 2.160. The company issued revenue guidance of $235.4 million-$242.8 million, compared to the consensus revenue estimate of $240.2 million. LeMaitre Vascular also updated its Q1 2025 guidance to 0.480-0.530 EPS.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the stock. Oppenheimer reissued an “outperform” rating and issued a $93.00 target price (up from $90.00) on shares of LeMaitre Vascular in a research note on Friday, November 1st. Barrington Research upped their target price on shares of LeMaitre Vascular from $92.00 to $93.00 and gave the stock an “outperform” rating in a report on Friday, November 1st. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Finally, Wells Fargo & Company assumed coverage on shares of LeMaitre Vascular in a research report on Thursday, February 13th. They set an “equal weight” rating and a $95.00 price objective on the stock. Three research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, LeMaitre Vascular has a consensus rating of “Moderate Buy” and an average price target of $94.63.

LeMaitre Vascular Stock Performance

Shares of LMAT traded down $3.14 during midday trading on Thursday, hitting $99.91. The company had a trading volume of 197,639 shares, compared to its average volume of 138,669. The firm has a market capitalization of $2.25 billion, a P/E ratio of 54.60, a P/E/G ratio of 2.22 and a beta of 0.96. The company’s 50-day simple moving average is $96.75 and its 200-day simple moving average is $94.62. LeMaitre Vascular has a 1 year low of $62.39 and a 1 year high of $109.58.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Thursday, February 27th. The medical instruments supplier reported $0.49 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.49. LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. Equities analysts predict that LeMaitre Vascular will post 1.94 earnings per share for the current fiscal year.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.